Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase I Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered as Single and Multiple Doses in the Fed State to Normal Healthy Male Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs SRT 2104 (Primary)
- Indications Chronic obstructive pulmonary disease; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors GSK
- 15 Jul 2009 New trial record